The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Psoriasis Triggered by Toll-like Receptor 7 Agonist Imiquimod in the Presence of Dermal Plasmacytoid Dendritic Cell Precursors
Abstract
BACKGROUND: It has been proposed that the innate immune system plays a central role in driving the autoimmune T-cell cascade leading to psoriasis; however, there is no direct evidence for this. OBSERVATIONS: We observed aggravation and spreading of a psoriatic plaque when treated topically with the toll-like receptor (TLR) 7 agonist imiquimod. The exacerbation of psoriasis was accompanied by a massive induction of lesional type I interferon activity, detected by MxA expression after imiquimod therapy. Since imiquimod induces large amounts of type I interferon production from TLR7-expressing plasmacytoid dendritic cell precursors (PDCs), the natural interferon-producing cells of the peripheral blood, we asked whether PDCs are present in psoriatic skin. We identified high numbers of PDCs in psoriatic skin lesions (up to 16% of the total dermal infiltrate) based on their coexpression of BDCA2 and CD123. By contrast, PDCs were present at very low levels in atopic dermatitis and not detected in normal human skin. CONCLUSIONS: This study shows that psoriasis can be driven by the innate immune system through TLR ligation. Furthermore, our finding that large numbers of PDCs infiltrate psoriatic skin suggests a role of lesional PDCs as type I interferon-producing targets for the TLR7 agonist imiquimod.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toll-like receptors: critical proteins linking innate and acquired immunity
Akira, S., Takeda, K., & Kaisho, T. (2001) · Nature Immunology · doi:10.1038/90609 · Cited by 4,777
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway
Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., & Akira, S. (2002) · Nature Immunology · doi:10.1038/ni758 · Cited by 2,522
The Nature of the Principal Type 1 Interferon-Producing Cells in Human Blood
Siegal, F. P., Kadowaki, N., Shodell, M., Fitzgerald-Bocarsly, P. A., Shah, K., Ho, S., Antonenko, S., & Liu, Y.-J. (1999) · Science · doi:10.1126/science.284.5421.1835 · Cited by 2,293
Kadowaki, N., Ho, S., Antonenko, S., de Waal Malefyt, R., Kastelein, R. A., Bazan, F., & Liu, Y.-J. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.863 · Cited by 1,964 · cited 2×
“Downloaded From: https://jamanetwork.com/ on 04/12/2022 ducer of type I IFNs in response to imiquimod is represented by plasmacytoid dendritic cell precursors (PDCs),18,19 a novel subset of lymphoid-related cells selectively expressing high levels of TLR7 and TLR9.”
BackgroundCella, M., Jarrossay, D., Facchetti, F., Alebardi, O., Nakajima, H., Lanzavecchia, A., & Colonna, M. (1999) · Nature Medicine · doi:10.1038/11360 · Cited by 1,737
Innate immune recognition: mechanisms and pathways
Medzhitov, R., & Janeway, C. J. (2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.917309.x · Cited by 1,506
Grouard, G., Rissoan, M.-C., Filgueira, L., Durand, I., Banchereau, J., & Liu, Y.-J. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.6.1101 · Cited by 1,189
A Toll-like Receptor That Prevents Infection by Uropathogenic Bacteria
Zhang, D., Zhang, G., Hayden, M. S., Greenblatt, M. B., Bussey, C., Flavell, R. A., & Ghosh, S. (2004) · Science · doi:10.1126/science.1094351 · Cited by 1,004
Natural Interferon α/β–Producing Cells Link Innate and Adaptive Immunity
Kadowaki, N., Antonenko, S., Lau, J. Y.-N., & Liu, Y.-J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.219 · Cited by 849
Jarrossay, D., Napolitani, G., Colonna, M., Sallusto, F., & Lanzavecchia, A. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200111)31:11<3388::aid-immu3388>3.0.co;2-q · Cited by 788
Keratinocytes as initiators of inflammation
Barker, J. N. W. N., Griffiths, C. E. M., Nickoloff, B. J., Mitra, R. S., Dixit, V. M., & Nickoloff, B. J. (1991) · The Lancet · doi:10.1016/0140-6736(91)92168-2 · Cited by 766
Dzionek, A., Sohma, Y., Nagafune, J., Cella, M., Colonna, M., Facchetti, F., Günther, G., Johnston, I., Lanzavecchia, A., Nagasaka, T., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.12.1823 · Cited by 766
Type I IFNs Enhance the Terminal Differentiation of Dendritic Cells
Luft, T., Pang, K. C., Thomas, E., Hertzog, P., Hart, D. N. J., Trapani, J., & Cebon, J. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.4.1947 · Cited by 611
Ito, T., Amakawa, R., Kaisho, T., Hemmi, H., Tajima, K., Uehira, K., Ozaki, Y., Tomizawa, H., Akira, S., & Fukuhara, S. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020207 · Cited by 466
Wollenberg, A., Günther, S., Moderer, M., Wetzel, S., Wagner, M., Towarowski, A., Tuma, E., Rothenfusser, S., Endres, S., & Hartmann, G. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.19515.x · Cited by 461
Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug
Miller, R. L., Gerster, J. F., Owens, M. L., Slade, H. B., & Tomai, M. A. (1999) · International Journal of Immunopharmacology · doi:10.1016/s0192-0561(98)00068-x · Cited by 417
Eriksson, U., Ricci, R., Hunziker, L., Kurrer, M. O., Oudit, G. Y., Watts, T. H., Sonderegger, I., Bachmaier, K., Kopf, M., & Penninger, J. M. (2003) · Nature Medicine · doi:10.1038/nm960 · Cited by 405
Gibson, S. J., Lindh, J. M., Riter, T. R., Gleason, R. M., Rogers, L. M., Fuller, A. E., Oesterich, J. L., Gorden, K. B., Qiu, X., McKane, S. W., et al. (2002) · Cellular Immunology · doi:10.1016/s0008-8749(02)00517-8 · Cited by 375
Fonteneau, J.-F., Gilliet, M., Larsson, M., Dasilva, I., Münz, C., Liu, Y.-J., & Bhardwaj, N. (2003) · Blood · doi:10.1182/blood-2002-10-3063 · Cited by 346
Self-citationIFNs activate toll-like receptor gene expression in viral infections
Miettinen, M., Sareneva, T., Julkunen, I., & Matikainen, S. (2001) · Genes & Immunity · doi:10.1038/sj.gene.6363791 · Cited by 282
Tumor-Selective Induction of Apoptosis and the Small-Molecule Immune Response Modifier Imiquimod
Schon, M., Bong, A. B., Drewniok, C., Herz, J., Geilen, C. C., Reifenberger, J., Benninghoff, B., Slade, H. B., Gollnick, H., & Schon, M. P. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg016 · Cited by 258
Mempel, M., Voelcker, V., Köllisch, G., Plank, C., Rad, R., Gerhard, M., Schnopp, C., Fraunberger, P., Walli, A. K., Ring, J., et al. (2003) · Journal of Investigative Dermatology · doi:10.1111/j.1523-1747.2003.12630.x · Cited by 256
Bendriss-Vermare, N., Barthélémy, C., Durand, I., Bruand, C., Dezutter-Dambuyant, C., Moulian, N., Berrih-Aknin, S., Caux, C., Trinchieri, G., & Brière, F. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11734 · Cited by 199
Mohty, M., Vialle-Castellano, A., Nunes, J. A., Isnardon, D., Olive, D., & Gaugler, B. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.7.3385 · Cited by 182
Cytokine induction in mice by the immunomodulator imiquimod
Reiter, M. J., Tester man, T. L., Miller, R. L., Weeks, C. E., & Tomai, M. A. (1994) · Journal of Leukocyte Biology · doi:10.1002/jlb.55.2.234 · Cited by 168
Treatment of lentigo maligna with topical imiquimod
Naylor, M. F., Crowson, N., Kuwahara, R., Teague, K., Garcia, C., Mackinnis, C., Haque, R., Odom, C., Jankey, C., & Cornelison, R. L. (2003) · British Journal of Dermatology · doi:10.1046/j.0366-077x.2003.05637.x · Cited by 167
Innate Immune-Related Receptors in Normal and Psoriatic Skin
Curry, J. L., Qin, J., Bonish, B. K., Carrick, R. P., Bacon, P. E., Panella, J. R., Robinson, J. K., & Nickoloff, B. J. (2003) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2003-127-178-iirrin · Cited by 159
Mechanisms Underlying Imiquimod-Induced Regression of Basal Cell Carcinoma In Vivo
Urosevic, M., Maier, T., Benninghoff, B., Slade, H. B., Burg, G., & Dummer, R. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.10.1325 · Cited by 145
Self-citationSkin innate immune system in psoriasis: friend or foe?
Nickoloff, B. J. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8633 · Cited by 121
Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer.
Seya, T., Akazawa, T., Uehori, J., Matsumoto, M., Azuma, I., & Toyoshima, K. (2003) · PubMed · Cited by 106
Imiquimod in basal cell carcinoma: how does it work?
Dummer, R., Urosevic, M., Kempf, W., Hoek, K. S., Hafner, J., & Burg, G. (2003) · British Journal of Dermatology · doi:10.1046/j.0366-077x.2003.05630.x · Cited by 78
Self-citationThe immunological basis of psoriasis
Griffiths, C. E. M. (2003) · Journal of the European Academy of Dermatology and Venereology · doi:10.1046/j.1468-3083.17.s2.1.x · Cited by 73
Pathogenesis of Psoriasis: Current Concepts
Kadunce, D. P., & Krueger, G. G. (1995) · Dermatologic Clinics · doi:10.1016/s0733-8635(18)30037-8 · Cited by 66
Transplantation of psoriatic skin onto nude mice.
Fräki, J. E., Briggaman, R. A., & Lazarus, G. S. (1983) · PubMed · Cited by 61
Treatment of molluscum contagiosum with imiquimod 5% cream
Skinner, R. B. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.126578 · Cited by 46
Cited by
Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E., & Barker, J. N. W. N. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32549-6 · Cited by 2,383
Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis
van der Fits, L., Mourits, S., Voerman, J. S. A., Kant, M., Boon, L., Laman, J. D., Cornelissen, F., Mus, A.-M., Florencia, E., Prens, E. P., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802999 · Cited by 2,176
Plasmacytoid predendritic cells initiate psoriasis through interferon-α production
Nestle, F. O., Conrad, C., Tun-Kyi, A., Homey, B., Gombert, M., Boyman, O., Burg, G., Liu, Y.-J., & Gilliet, M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050500 · Cited by 1,124
Self-citationPivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation
Cai, Y., Shen, X., Ding, C., Qi, C., Li, K., Li, X., Jala, V. R., Zhang, H.-G., Wang, T., Zheng, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.08.001 · Cited by 1,026
Gottenberg, J.-E., Cagnard, N., Lucchesi, C., Letourneur, F., Mistou, S., Lazure, T., Jacques, S., Ba, N., Ittah, M., Lepajolec, C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510837103 · Cited by 611
Metadata
- Authors
- Gilliet, M., Conrad, C., Geiges, M., Cozzio, A., Thürlimann, W., Burg, G., Nestle, F. O., & Dummer, R.
- Venue
- Archives of Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2004-12-01
- Volume
- 140
- Issue
- 12
- Pages
- 1490-5
- ISSN
- 0003-987X (ISSN-L)
- OpenAlex
- W2058863496
- Cited by
- 408
- References
- 37
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.